Trial Profile

A study of VY-SOD101 for a treatment of monogenic form of Amyotrophic lateral sclerosis (ALS)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VY SOD101 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions

Most Recent Events

01 Nov 2017 According to a Voyager Therapeutics media release, company plans to file IND in 2019.
20 May 2016 New trial record
12 May 2016 According to a Voyager Therapeutics media release, the company expects to file an Investigational New Drug (IND) application for VY-SOD101 in late 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com